Clinicalprojects International GmbH (CPI), an independent contract research organization, announced that the company is continuing its growth into new therapeutic areas for the development of biopharmaceuticals and medical devices.

CPI started offering clinical development services in 2007 as a young clinical research organization (CRO) in intensive care medicine with a special focus on sepsis. In the interim, the company has successfully expanded its clinical operations and regulatory services in further therapeutic areas across Europe. In addition to its core expertise in the management of phase II and phase III clinical trials, CPI further expanded its range of services to cater for observational studies beginning of 2009. The company’s current clients include international bio pharmaceutical and medical device companies, and CPI's repeat business has been a major factor in driving the business forward. 

The company provides a full range of clinical development services to biotechnology, pharmaceutical and medical device clients from phase II to phase IV. Its key focus is the delivery of a continuous stream of quality data, at the same time achieving targeted enrolment, and respecting project timelines and budget goals.

Joerg W. Breitkopf, managing director of Clinicalprojects International GmbH said, “The year 2010 will be another very important year for continuing development of the company. Our plans include geographic expansion into other European markets, and plans for Italy, Spain and the UK in particular are very close to realisation.”

In January 2009, a communication about a tentative merger plans with a US-based company, but such plans did not come to fruition. Breitkopf commented,”CPI has both the infrastructure and the client base to further develop itself as an independent organization in 2010 and the future”.